Revascular Bio receives JPY220m investment from OUVC
The financing supports cell-product manufacturing development for difficult-to-treat skin ulcers.
Revascular Bio Co., Ltd. has received a JPY220 million investment from the OUVC2 fund, managed by Osaka University Venture Capital. The investment was completed on November 10, 2023.
The proceeds will support development of cell products for difficult-to-treat skin ulcers, including the transfer of endothelial stem-cell expansion methods to cell-processing facilities. The company will also continue haemophilia research.
Revascular Bio builds on Osaka University research into vascular endothelial stem cells. It aims to turn their ability to maintain and regenerate blood vessels into therapeutic products.
Use of funds
Develop cell manufacturing for difficult-to-treat skin ulcers
Transfer endothelial stem-cell expansion methods to cell-processing facilities